p53 mutation is commonly associated with high-grade, high-stage human urothelial carcinomas. Recent studies suggest that p53 mutation in low-grade, low-stage bladder carcinomas may be correlated with the progression of the disease. In the present study, we used antisense RNA methodology in vitro to evaluate the significance of the loss of p53 function at an early stage of urinary bladder carcinogenesis. An immortalized nontumorigenic rat urothelial cell line (MYP3) that strongly expresses wild-type (WT) p53 was transfected with a plasmid (pcDL-SRα-296) containing a rat WT p53 cDNA in antisense orientation. The transfection resulted in a significant reduction in p53 mRNA expression and protein synthesis, in stimulation of anchorage-dependent growth, and in acquisition of anchorage-independent growth potential. Three such clones, when tested in athymic nude mice, all formed muscle-invasive, high-grade transitional cell carcinomas at s.c. injection sites. When cells were inoculated into an orthotopic site (urinary bladder), one of two antisense transfectants tested formed bulky tumors in the bladder in all seven nude mice and metastases to lungs in three of the seven mice. Analysis of these cells revealed a decrease in the expression of p21 (WAF1, sdi1, or CIP1) and retinoblastoma (Rb) gene product. Phosphorylation of Rb protein was not inhibited when the cells were starved. No significant difference was observed in the expression of p16 protein.
Introduction
The p53 gene was identified as a tumor-suppressor gene because of its ability to inhibit malignant transformation (1, 2) . Mutations or deletions of the p53 gene are the most frequent molecular event in human oncogenesis (2, 3) . In urinary bladder carcinogenesis, p53 gene deletion or mutation is associated with high-grade, high-stage human urothelial carcinomas (4) (5) (6) (7) (8) , and it may be involved in the progression of superficial to deeply invasive bladder cancer (9) . However, recent human and animal studies also indicate that p53 gene inactivation may occur in an early stage of bladder carcinogenesis (10, 11) , and that p53 gene mutation in carcinoma in situ or superficial bladder cancer is associated with a high rate of disease progression (12, 13) .
In the present study, to examine the significance of the early loss of p53 function in urinary bladder carcinogenesis in vitro, we used antisense RNA methodology. We introduced wildtype (WT*) p53 cDNA in an antisense orientation under the control of the SRα promoter into a rat nontumorigenic urothelial cell line, MYP3, that strongly expresses WT p53.
Materials and methods

Cells and cell culture
MYP3 is a hyperdiploid (44, XY, ϩ1, ϩ7) cell line which maintains the characteristics of epithelial cells in culture. The cells do not form tumors in nude mice, nor do they form colonies in soft agar (14) . The cells were grown in Ham's F12 medium (Life Technologies, Inc., Gaithersburg, MD) supplemented with 10% FCS (Life Technologies, Inc.), 10 µM non-essential amino acids (Life Technologies, Inc.), 2.7 mg/ml dextrose (Sigma, St Louis, MO), 1 µg/ml hydrocortisone (Sigma), 5 µg/ml transferrin, 10 µg/ml insulin, 10 ng/ml epidermal growth factor, 100 µg/ml streptomycin, and 100 U/ml penicillin (all from Life Technologies, Inc.) in a humidified atmosphere of 95% air and 5% CO 2 at 37°C. This medium was designated as complete medium. There is no activating mutation in the p53 gene in MYP3 when examined by polymerase chain reaction (PCR)-single-strand conformation polymorphism analysis (Okamoto and Oyasu, unpublished observations).
Preparation of rat WT p53 cDNA and plasmid construction
Rat WT p53 cDNA was prepared from mRNA of MYP3 cells by reverse transcriptase (RT)-PCR. The two nucleotide bases used were 5Ј-gaattcatggaggattcacagtcg-3 as an up-stream primer and 5Ј-gaattcagctctcggaacatctcg-3Ј as a down-stream primer (15) . Additional nucleotides for EcoR1 sites were linked to both primers at their 5Ј end. One µg of total RNA was reversetranscribed by Moloney murine leukemia virus reverse transcriptase (Life Technologies, Inc.) at 42°C for 60 min in a 10 µl mixture with the downstream primer. One µl of RT mixture was subjected to PCR in a 20 µl mixture [10 mM Tris-HCl, pH 8.3, 50 mM KCl, 1.5 mM MgCl 2 , 0.01% gelatin, 20 mM each dNTP (A,G,T,C), 0.5 U Taq polymerase (Cetus Perkin-Elmer, Norwalk, CT), and 0.25 pmol primer] (16). Forty cycles of reaction at 94, 55, and 72°C for 60, 90, and 150 s, respectively, were run in a DNA thermal cycler (Cetus Perkin-Elmer). The PCR products (1029 bp; exons 1-9) were digested with EcoR1 and purified by preparative gel electrophoresis and the Geneclean II kit (BIO 101 Inc., La Jolla, CA). The purified fragment was ligated to the EcoR1 site of pcDL-SRα296 (provided by Dr Yutaka Takebe) in sense and antisense orientation. This is a mammalian expression vector under the transcriptional control of the SRα promoter (the simian virus 40 early promoter and the R-U5 sequence from the long terminal repeat of human T-cell leukemia virus type I) (17) . The insert as a rat WT p53 cDNA fragment was confirmed by nucleotide sequencing. These recombinant plasmids containing sense-or antisense-oriented rat WT p53 cDNA fragment were designated as pSRα-p53S and pSRα-p53AS, respectively ( Figure 1A ). The direction of the ligated fragment from the promoter was confirmed by restriction enzyme digestion with Pst1 (Life Technologies, Inc.).
Transfection
Cells (5ϫ10 5 cells/dish) were seeded in 100 mm culture dishes (Falcon, Lincoln Park, NJ) in the complete medium. Twenty-four h later, the cells were transfected with 20 µg of either pSRα-p53S or pSRα-p53AS mixed with 1 µg of a selectable vector, pSV2neo (provided by Dr Yousuke Ebina), by the polybrene method (18) . The cells were incubated for 24 h in the complete medium and then trypsinized and seeded at a 1:5 ratio in 100 mm culture dishes in the complete medium. Forty-eight h later, the cells were switched to a selective medium containing Geneticin (800 µg/ml G418; Life Technologies, Inc.). After 14 days of culture in the selective medium, G418-resistant clones were isolated and expanded in a 24-well cluster dish (Falcon).
Isolation of RNA and Northern blot analysis
Cells grown in monolayers were harvested at early confluency. RNA was prepared by lysing of cells in hypotonic buffer containing Nonidet P-40 (Sigma), followed by removal of nuclei as previously described (19) . Poly A ϩ RNA was isolated by oligo-dT cellulose (Collaborative Research, Bedford, MA). Cytoplasmic RNA (20 µg) or Poly A ϩ RNA (1 µg) was electrophoresed onto a formaldehyde/1.0% agarose gel, blotted onto a nylon filter (ICN Biomedicals, Irvine, CA), and hybridized with 32 P-labeled cDNA probes or RNA probes. The cDNA probes used were a 1.0 kb EcoR1-EcoR1 fragment of pSRα-p53AS for rat p53, and a 2.1 kb Xho 1-Xho 1 fragment of the pHFβA-1 for β-actin (American Type Culture Collection, Rockville, MD). Rat Interleukin (IL)-6 cDNA was prepared from mRNA of primary-culture stromal cells derived from rat bladder by RT-PCR as described above. The two nucleotide bases used were 5Ј-ATGAAGTTTCTCTCCGCAAGAGAC-3Ј as an up-stream primer and 5Ј-TTGCTCTGAATGACTCTGGCTTTG-3Ј as a down-stream primer (20) . The PCR products (433 bp) were subcloned into the pCR TM II vector with the use of a TA cloning kit (Invitrogen, San Diego, CA). The insert as a rat IL-6 cDNA fragment was confirmed by nucleotide sequencing. The 452 bp EcoR1-EcoR1 fragment containing rat IL-6 cDNA was excised from the vector and was used as a probe. A 1.0 kb EcoR1-EcoR1 fragment of pSRα-p53AS for rat p53 was ligated to the EcoR1 site of pGEM-4Z (Promega, Madison, WI), and then sense-and antisenseoriented RNA probe for rat p53 was prepared with a commercial kit (Riboprobe Gemini II Core System, Promega).
Western blot analysis
Cells were starved by culturing in F-12 medium containing 0.1% FCS. Zero to 72 h later, cells were harvested by centrifugation, washed once with ice- 
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cold phosphate-buffered saline (PBS), and lysed on ice for 30 min in 0.9% PBS containing 1% NP40, 10 µg/ml leupeptin, 10 µg/ml aprotinin, 2 mM 4-(2-aminoethyl) benzenesulfonyl fluoride, 1 mM sodium o-vanadate, 10 mM sodium fluoride, and 5 mM sodium pyrophosphate. The samples were centrifuged at 4°C for 15-20 min, and supernatants were transferred into new tubes. The samples (100 µg protein/lane) were electrophoresed on SDSpolyacrylamide gel. Proteins from gels were transferred to nitrocellulose (BioRad, Hercules, CA), and p53, WAF1/p21, Rb, and p16 were detected, respectively, with mouse anti-p53 monoclonal antibody (Ab-1; Oncogene Science, Uniondale, NY), rabbit anti-WAF1 polyclonal antibody (Oncogene Science), mouse anti-retinoblastoma (Rb) gene product antibody (Triton Biosciences Inc., Alameda, CA), rabbit anti-p16 polyclonal antibody (M-156; Santa Cruz Biotechnology Inc., Santa Cruz, CA), and an ECL kit (Amersham, Arlington Heights, IL).
Cell cycle determination
Cells were starved by culturing in F-12 medium containing 0.1% FCS. Zero to 48 h later, cells were harvested by centrifugation, washed, and fixed in icecold 70% ethanol. Cells were then washed with PBS, treated with RNase (500 units/ml; Sigma) at 37°C for 15 min, and finally stained with propidium iodide at 50 µg/ml in PBS. Cell cycle analysis was performed with a fluorescence-activated cell analyzer (Coulter Co., Miami, FL) and fitting program, MOD-Fit (Verity Software House Inc., Topsham, MA).
Anchorage-dependent growth
Cells were grown for 24 h in a 96-well plate containing the complete medium. Then cells were cultured in F-12 medium containing 0.1% FCS in flat-bottom 96-well plates (Falcon) at 1.0ϫ10 4 cells per well. After 0-4 days of culture, cell proliferation was assessed by addition of 20 µg of the vital dye 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyl tetrazolium bromide (MTT, 1 mg/ml; Sigma) for 4 h. The blue dye taken up by cells was dissolved in dimethylsulfoxide (100 µl/well), and its optical density at 495 nm was read on an automated microplate reader (Bio-Tec, Winooski, VT) (21) . A preliminary study with the MTT assay showed that there was no quantitative difference in absorbance between MYP3 and its transfectants. Thus, we were able to use absorbance for estimating the number of cells without specific correction. Anchorage-independent growth Cells were seeded at a density 1ϫ10 4 cells/35 mm dish in 2 ml of 0.3% Noble agar (Difco, Detroit, MI) in the complete medium. This suspension was layered over 2 ml of 0.6% agar in the complete medium in 35 mm dishes (Falcon). The cells were incubated in a humidified atmosphere of 95% air and 5% CO 2 at 37°C. One ml of 0.3% agar in the complete medium was added at days 9 and 18. After 28 days, colonies of Ͼ20 cells were counted.
Tumorigenicity in athymic nude mice
After trypsinization, cells were washed twice with Ham's F-12 medium without serum and resuspended in 0.2 ml of the medium without serum or 0.2 ml of 50% Matrigel (Collaborative Reseach) diluted with the same medium. Groups of six male athymic BALB/c nude mice (Harlan Sprague Dawley Inc., Indianapolis, IN) received 5ϫ10 6 cells injected s.c. at each dorsal flank. The mice were monitored twice a week for the development of tumors, and then killed after 11-13 weeks. The tumors at the inoculation sites were removed and examined microscopically.
In addition, tumorigenicity of the transfectants was assessed in the nudemouse heterotopically transplanted urinary bladder (HTB) model which was developed in our laboratory as an orthotopic test site (22) . It consists of a rat bladder transplanted into the retroperitoneal space and connected to a reservoir placed s.c. in a nude mouse. Viable cells (5ϫ10 6 ) suspended in 0.5 ml of serum-free medium were instilled into the HTB, which was pre-treated with 1.0% Nonidet P-40 and Matrigel as reported previously (22) . The mice were observed at least twice a week and were killed 19-25 weeks after inoculation. At autopsy, the transplanted bladder, lymph nodes (paraaortic, subclavian, and axillary), lungs, liver, spleen, and kidneys were examined for the presence of grossly recognizable tumors and processed for routine histologic examination.
Preparation of conditioned medium (CM) and enzyme-linked immunosorbent assay for IL-6
Cells were grown to confluency (~2.5ϫ10 6 cells/dish) in 100 mm dishes (Falcon) in the complete medium, washed 3 times with the serum-free F-12 medium, and cultured for an additional 48 h in 10 ml of the serum-free medium. The medium was collected and clarified by centrifugation at 5000 rpm. The concentration of IL-6 in CM was measured by enzyme-linked immunosorbent assay with the use of polyclonal rabbit anti-human IL-6 (Genzyme) as a solid phase antibody and monoclonal mouse anti-human IL-6 (Genzyme) as a second antibody. Both antibodies are known to react to rat IL-6. The assay detected IL-6 at 10 pg/ml or higher in a linear fashion. Results were expressed as pg/ml of CM.
Results
Isolation of antisense transfectants that express a reduced level of p53
MYP3 cells were transfected with an expression vector containing antisense-oriented rat p53 cDNA under transcriptional control of the SRα promoter ( Figure 1A ). Five clones (p53AS-1, p53AS-3, p53AS-4, p53AS-C, p53AS-E) were isolated. They showed a marked reduction in both p53 mRNA and protein as compared to the control cells transfected with only pSV2neo (MYP3neo). Northern blot analysis with an antisenseoriented RNA probe for sense p53 mRNA demonstrated a marked reduction in the expression of p53 mRNA in all of these transfectants ( Figure 1B ). All transfectants also showed a significant decrease in p53 protein ( Figure 1D ) by Western blot analysis. We confirmed the expression of antisense transcripts of rat p53 in all five transfectants by Northern blot analysis with a sense-oriented RNA probe ( Figure 1C ). Unique integration of rat p53 cDNA was confirmed by PCR and Southern blot analysis (data not shown). Growth potential of antisense transfectants on plastic surface and in soft-agar culture All transfectants with introduced antisense RNA demonstrated higher cell counts than did MYP3neo [163%-173% of the control cells (MYP3neo; P Ͻ 0.001), when counted on day 4] (Figure 2A ). The cells transfected with sense-oriented rat p53 cDNA (p53S) showed a growth potential similar to that 75 of MYP3neo (Figure 2A) . In soft-agar assay, all transfectants with antisense RNA formed colonies (89-367/1ϫ10 4 cells) ( Figure 2B ), whereas MYP3neo and p53S did not ( Figure 2B ). Tumorigenicity and metastasis assay in athymic nude mice p53AS-3, 4, and C, which showed a higher growth potential than did other transfectants both on a plastic surface and in soft agar (Figure 2) , and MYP3neo as a negative control (5ϫ10 6 cells) were injected s.c. at the dorsal flanks of nude mice with or without 50% Matrigel. MYP3neo did not form tumors. In contrast, all clones expressing the antisense RNA formed tumors with or without Matrigel (Table I ). Microscopic Cells (5ϫ10 6 ) were injected s.c. in dorsal flanks of nude mice with or without 50% Matrigel. The mice were monitored twice a week for appearance of tumors and were killed after 11-13 weeks. 6 ) suspended in 0.5 ml of serum-free medium were instilled into the nude mouse HTB which was pre-treated with 1.0% Nonidet P-40 and Matrigel to remove the preexisting normal epithelial cells as reported previously (22) . The mice were killed 19-25 weeks after inoculation.
examination showed them to be high-grade transitional cell carcinomas. The tumorigenicity of the cells was also tested at an orthotopic site, namely, in our unique nude-mouse HTB system. All seven mice receiving p53AS-3 cells formed bulky tumors (Table II and Figure 3A and B). They were high-grade, poorly differentiated transitional cell carcinomas which were deeply invasive through the muscle layer. Multiple foci of pulmonary metastatsis were observed in three of the seven mice (Table  II and Figure 3C ). In contrast, p53AS-4 cells as well as control MYP3neo did not form tumors in either the bladder or the lungs.
Expression of IL-6 mRNA and IL-6 release into CM by antisense transfectants
Because p53 was reported to be involved as a transcriptional repressor of IL-6 gene expression during cellular differentiation and oncogenesis (23) (24) (25) , we examined the effect of antisense transfection on the expression of IL-6 mRNA and protein. All antisense transfectants demonstrated IL-6 mRNA at significantly higher levels than did MYP3neo ( Figure 4A ). IL-6 was secreted into CM by p53AS-3, p53AS-4, and p53AS-C (289 Ϯ 18, 216 Ϯ 31, and 107 Ϯ 10 pg/ml/48 h/2.5ϫ10 6 cells, respectively) at much higher levels than that by MYP3neo or p53S (4.9 Ϯ 0.6 and 3.9 Ϯ 0.5 pg/ml/48 h/2.5ϫ10 6 cells, respectively) ( Figure 4B ).
Effect of anti-IL-6 antibody on growth of antisense transfectants
We demonstrated in our previous report that MYP3 had IL-6 receptor and that its growth was stimulated by exogenous IL-6 (26) . Therefore, we added polyclonal rabbit anti-human IL-6 antibody (50 µg/ml) to the medium of the antisense transfectants. Its neutralizing activity as well as its specificity for IL-6 have been confirmed by complete inhibition of the mitogenic effect of recombinant IL-6 (27; our own data, unpublished). In all antisense transfectants tested, growth was suppressed significantly by the addition of anti-IL-6 antibody (P Ͻ 0.001, Figure 4C ).
Expression of p53, Rb protein and the negative cell cycle regulators WAF1/p21 and p16
Both p53 and Rb proteins play a major role in the control of the cell cycle in G 0 -G 1 phase. Expression of Rb is regulated directly at the transcriptional level (28, 29) as well as indirectly (30) by p53. The underphosphorylated form of Rb, which exists as a complex with transcription factors E2F, is believed to be the functionally active form of Rb and to exert a negative effect on the cell cycle. Its phosphorylation releases E2F, and the unbound E2F stimulates transcription of cellular genes implicated in the induction of S phase (30) . Rb protein is a target for the enzymatic activity of cyclin-cyclin dependent kinase (CdK) complexes. p21 is transcriptionally regulated by p53 and inactivates cyclin E-CdK2, cyclin A-CdK2, cyclin D1-, D2-and D3-CdK4 complexes, and consequently it inhibits Rb phosphorylation (30, 31) . p15, p16, and p21 also function as cyclin-dependent kinase inhibitors and contribute to cell cycle arrest by inhibiting phosphorylation of Rb.
We examined the cell lysates of the transfectants for the expression of p53, WAF1/p21, Rb protein and its phosphoryl- ated fraction, and p16 by Western blot analysis. Because DNA-damaging factors, including irradiation, or starvation by deprivation of serum or growth factors, are reported to increase p53 and WAF1/p21 expression and inhibit the phosphorylation of Rb in a variety of benign and malignant cells (32, 33) , cells were starved by culturing in F12 medium containing 0.1% FCS for 0-72 h. Before starvation (0 h), p53 protein was observed at a low level only in MYP3neo and not in p53AS-3 or -4 ( Figure 5A ). This finding was similar to that shown in Figure 1D . After starvation, the levels of the protein increased markedly in MYP3neo. In the antisense transfectants tested (p53AS-3 and -4), p53 protein was not detectable at all or only at a trace level ( Figure 5A ). Before starvation, the level of the expression of both WAF1/p21 and Rb proteins was lower in both antisense transfectants than that in the control MYP3neo cells. After 24 h of starvation, a marked increase in the expression of WAF1 protein and a reduction in phosphorylated Rb protein were observed in the control MYP3neo.
In both transfectants, only a trace increase in WAF1 and no significant alterations in both phosphorylated and unphosphorylated Rb protein were observed irrespective of the duration of starvation ( Figure 5B) . Thus, the ratio of phosphorylated to underphosphorylated protein decreased in the control MYP3-77 6 . Cell cycle analysis of p53 antisense transfectants. Cells were starved for 0-48 h in F-12 medium containing 0.1% FCS, harvested, and fixed in ice-cold 70% ethanol. Cells were then treated with RNase (500 units/ml) at 37°C for 15 min and finally stained with propidium iodide at 50 µg/ml in PBS. Cell cycle analysis was performed with a fluorescence-activated cell analyzer.
neo, but remained unchanged in the transfectants. There was no significant difference in p16 protein levels among the cell lines tested, nor was there any change in their expression by starvation (data not shown).
Cell cycle determination in p53 antisense transfectants
The cells (MYP3neo, p53AS-3 and -4) which were starved for 0-48 h were examined for their cell cycle status by flow-cytometric analysis. G 1 arrest was observed in MYP3neo after starvation (G 0 -G 1 fraction; 62.2% before starvation, 87.0% after starvation; Figure 6 ). In contrast, antisense transfectants showed an escape from G 1 arrest by starvation (G 0 -G 1 fraction; 43.5% and 46.4%, respectively, before and after starvation) in p53AS-3 or a minimal effect on cell cycle (44.9% and 60.7%, respectively, before and after starvation) in p53AS-4 ( Figure  6 ). The findings were in keeping with the growth curves depicted in Figure 2 .
Discussion
Mutations or deletions of the p53 tumor suppressor gene are the most frequent molecular event in human oncogenesis (2, 3) . Recent reports indicate that p53 gene mutations occur not only in the advanced stage of bladder cancer, but also in superficial (low-stage) bladder carcinoma, dysplasia, and carcinoma in situ and that superficial bladder cancer or carcinoma in situ with p53 gene mutations is associated with a high rate of disease progression (10) (11) (12) . Although the above observation suggests a causal role of p53 alterations in the progression of the disease, evidence to support the suggestion is currently not available. The present study was an attempt to evaluate the significance of the loss of p53 function at an early stage of urinary bladder neoplasia. Our strategy was to utilize an immortalized nontumorigenic rat urothelial cell line, MYP3, which strongly expresses WT p53, to inhibit p53 gene function by transfection with a plasmid containing a rat WT p53 cDNA in antisense orientation, and to evaluate the effects in vivo and in vitro. We observed a significant reduction of p53 mRNA expression and protein production, a marked increase in growth rate on a plastic surface, acquisition of anchorage-independent growth, and tumorigenicity and metastatic potential in nude mice. Thus, the marked alterations in biological behavior are impressive: our observations indicate that p53 is indeed a powerful suppressor of oncogenicity, and that its inactivation in a nontumorigenic urothelial cell line is sufficient to convert it to a fully malignant phenotype. In view of the fact that p53 is a transcription factor and mediates arrest of the cell cycle in the G 1 phase after sublethal DNA damage, we examined the expression of some of the genes involved in the cell cycle. In the control cells, p53 protein level increased markedly associated with an increase in WAF1 protein. Unphosphorylated Rb protein remainded unchanged but the phosphorylated fraction was reduced markedly. These were all anticipated results because WAF1 and Rb expression is positively controlled by p53 protein. The reduction of phosphorylated Rb was attributed to the inhibitory effect of WAF1 protein on CDKs. The clones with introduced antisense p53 RNA showed a marked decrease in WAF1/p21 and Rb gene products. Phosphorylation of Rb protein was not inhibited by starvation. These changes could be accounted for by the reduced level of p53. On the other hand, there was no effect on the expression of p16. This was in contrast to the loss of p16 in human urothelialized cells immortalized with human papillomavirus 16E6, which binds and inactivates p53 (34) . Additionally, we confirmed that p53 antisense transfectants showed an escape from G 1 arrest after starvation unlike control MYP3neo by cell cycle analysis.
We also examined the expression of IL-6 because p53 has been shown to be a transcriptional repressor in modulating IL6 gene expression and oncogenesis (23) (24) (25) . The transfectants showed a marked increase in the secretion of IL-6 into the 78 culture medium, and anti-IL-6 antibody inhibited their growth significantly. Thus, an antisense p53-mediated increase in IL-6 production is one of the genes altered by inactivation of p53 and may play an important role in bladder carcinogenesis. This mechanism has been suggested by us recently (26) .
It is of considerable interest that one of the transformants, p53AS-3, formed invasive tumors in the orthotopic model (HTBs), whereas the other line, p53AS-4, did not, even though both were tumorigenic when tested at a heterotopic site (subcutaneous tissue). p53AS-3 formed more colonies in soft agar culture and secreted more IL-6 than did p53AS-4, and p53AS-4 expressed WAF1/p21 and Rb protein slightly more than did p53AS-3. Moreover, p53AS-3 escaped from G 1 arrest more than did p53AS-4 when they were starved. It is unlikely, however, that these minor differences are responsible for the failure of p53AS-4 to form tumors at the orthotopic test site (HTBs). It appears that the gene alterations associated with p53AS-4 are sufficient to allow growth in subcutaneous tissue, but insufficient to do so in the urinary bladder. It is well known that inactivation of p53 by mutation or deletion frequently causes spontaneous transformation in a variety of cells (35, 36) . In our future investigations, we will attempt to identify the gene(s) that are altered by inactivation of p53 in vitro and in vivo.
